Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Trial Profile

Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2010

At a glance

  • Drugs Emtricitabine; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Rilpivirine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Nov 2010 This bioequivalence study conducted by Gilead provides support for the Gilead NDA submitted to the US FDA for emtricitabine/rilpivirine/tenofovir disoproxil fumarate [Truvada/TMC278], according to a Gilead Sciences media release.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top